| 货号 | 12594T |
| 目标/特异性 | Each antibody in the HSP27 Antibody Sampler Kit recognizes endogenous levels of its specific target. Activation state antibodies detect their intended targets only when phosphorylated at the indicated site. |
| 供应商 | CST |
| 背景 | Heat shock protein (HSP) 27 is one of the small HSPs that are constitutively expressed at different levels in various cell types and tissues. Like other small HSPs, HSP27 is regulated at both the transcriptional and posttranslational levels (1). In response to stress, the HSP27 expression increases several-fold to confer cellular resistance to the adverse environmental change. HSP27 is phosphorylated at Ser15, Ser78, and Ser82 by MAPKAPK-2 as a result of the activation of the p38 MAP kinase pathway (2,3). Phosphorylation of HSP27 causes a change in its tertiary structure, which shifts from large homotypic multimers to dimers and monomers (4). It has been shown that phosphorylation and increased concentration of HSP27 modulates actin polymerization and reorganization (5,6). |
| 存放说明 | -20C |
| 参考文献 | Arrigo, A.P. and Landry, J. (1994) Cold Spring Harbor Laboratory Press, NY, 335-373. Landry, J. et al. (1992) J. Biol. Chem. 267, 794-803. Rouse, J. et al. (1994) Cell 78, 1027-1037. Rogalla, T. et al. (1999) J. Biol. Chem. 274, 18947-18956. Lavoie, J. et al. (1993) J. Biol. Chem. 268, 24210-24214. Rousseau, S. et al. (1997) Oncogene 15, 2169-2177. |
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO* is added and emits light during enzyme catalyzed decomposition. | |
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO* is added and emits light during enzyme catalyzed decomposition. | |
Western blot analysis of extracts from HeLa and COS-7 cells using HSP27 (G31) Mouse mAb. | |
Western blot analysis of extracts from HeLa and COS cells, untreated, anisomycin-treated or UV-treated, using Phospho-HSP27 (Ser78) Antibody (upper) or HSP27 (G31) mAb #2402 (lower). | |
Western blot analysis of extracts from HeLa and COS cells, untreated, anisomycin-treated or UV-treated, using Phospho-HSP27 (Ser15) Antibody (upper) or HSP27 (G31) Monoclonal Antibody #2402 (lower). | |
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, untreated (left panels) or lambda phosphatase-treated (right panels), using Phospho-HSP27 (Ser82) Antibody #2401 (upper panels) or HSP27 (G31) Mouse mAb (lower panels). | |
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Phospho-HSP27 (Ser78) Antibody. | |
Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using Phospho-HSP27 (Ser78) Antibody. | |
Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using HSP27 (G31) Mouse mAb. | |
Flow cytometric analysis of HeLa cells, untreated (blue) or UV treated (green), using Phospho-HSP27 (Ser78) Antibody compared to a nonspecific negative control antibody (red). | |
Confocal immunofluorescent analysis of A549 cells using HSP27 (G31) Mouse mAb (green). Red = Propidium iodide (fluorescent DNA dye). | |
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 (-) or SignalSilence® HSP27 siRNA I (+) using HSP27 (G31) Mouse mAb and p44/42 MAPK (Erk1/2) (3A7) Mouse mAb #9107. The HSP27 (G31) Mouse mAb confirms silencing of HSP27 expression, while the p44/42 MAPK (Erk1/2) (3A7) Mouse mAb is used to control for loading and specificity of HSP27 siRNA. | |
Immunohistochemical analysis of paraffin-embedded HeLa cell pellets, control (left) or UV-treated (right), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb. | |
Immunohistochemical analysis of paraffin-embedded human prostate carcinoma using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb. | |
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, control (left) or λ phosphatase-treated (right), using Phospho-HSP27 (Ser82) (D1H2) XP® Rabbit mAb. |
